Compare HCKT & TLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HCKT | TLSI |
|---|---|---|
| Founded | 1991 | 2010 |
| Country | United States | United States |
| Employees | N/A | 102 |
| Industry | Professional Services | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 324.6M | 270.2M |
| IPO Year | 1998 | N/A |
| Metric | HCKT | TLSI |
|---|---|---|
| Price | $13.08 | $4.51 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $17.00 | $7.00 |
| AVG Volume (30 Days) | ★ 217.4K | 137.9K |
| Earning Date | 05-05-2026 | 05-14-2026 |
| Dividend Yield | ★ 3.73% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.46 | N/A |
| Revenue | ★ $285,862,000.00 | N/A |
| Revenue This Year | $2.55 | $35.45 |
| Revenue Next Year | $5.07 | $37.58 |
| P/E Ratio | $28.05 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $12.19 | $3.42 |
| 52 Week High | $26.74 | $7.95 |
| Indicator | HCKT | TLSI |
|---|---|---|
| Relative Strength Index (RSI) | 45.96 | 53.50 |
| Support Level | $12.42 | $4.28 |
| Resistance Level | $14.67 | $4.83 |
| Average True Range (ATR) | 0.52 | 0.23 |
| MACD | 0.00 | 0.03 |
| Stochastic Oscillator | 34.88 | 55.67 |
The Hackett Group Inc is an IP platform-based Generative Artificial Intelligence (Gen AI) strategic consulting and executive advisory digital transformation firm. The Hackett Group provides dedicated expertise in Gen AI-enabled enterprise transformation services across the front, mid and back office areas, including its highly recognized Oracle, SAP, OneStream and Coupa implementation offerings. It operates in three segments Oracle Solutions, SAP Solutions, and Global S&BT. It generates the majority of its revenue from the Global S&BT segment in the United States.
TriSalus Life Sciences Inc is an oncology-focused medical technology business integrating its delivery technology with standard-of-care therapies and its investigational immunotherapeutic, nelitolimod, a class C Toll-like receptor 9 (TRL9) agonist, for patients with solid tumors. The company developed Pressure-Enabled Drug Delivery (PEDD) to overcome high intratumoral pressure and off-target delivery. Its 510(k) cleared device, the TriNav Infusion System using PEDD technology, is used for interventional radiology procedures including transarterial radioembolization (TARE) and transarterial chemoembolization (TACE) in patients with primary liver cancer or liver metastases. It has one reportable segment and generates revenue from sales of PEDD infusion systems, principally related to TriNav.